Myriad Genetics Stock

Myriad Genetics Interest Coverage

The Interest Coverage Ratio of Myriad Genetics (MYGN) as of Aug 6, 2026 is -7.79. In the previous year, Interest Coverage Ratio was -111.27 — a change of -93.00% (higher).

Interest Coverage

-7.79

YoY

-93.00%

Last updated:

Interest Coverage Ratio of Myriad Genetics is 2026 -7.79 . Interest Coverage Ratio of Myriad Genetics was 2025 -111.27 . It decreases by -93.00% higher compared to the previous year.
Access this data via the Eulerpool API

Myriad Genetics Stock analysis

What does Myriad Genetics do? Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myriad Genetics stock

Interest Coverage Ratio of Myriad Genetics is -7.79 in 2026.

Interest Coverage Ratio of Myriad Genetics changed from -111.27 to -7.79, representing a -93.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Myriad Genetics since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Myriad Genetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Myriad Genetics

All Key Metrics — Myriad Genetics